Clinical trial
A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia
NCT04042376 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 18, 2019
- Completion date
- March 19, 2024
- Enrollment
- 17 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.